Found: 6
Select item for more details and to access through your institution.
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer.
- Published in:
- Cancers, 2023, v. 15, n. 10, p. 2814, doi. 10.3390/cancers15102814
- By:
- Publication type:
- Article
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 2, p. 385, doi. 10.1002/ijc.33306
- By:
- Publication type:
- Article
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
- Published in:
- 2022
- By:
- Publication type:
- corrected article
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
- Published in:
- Theranostics, 2024, v. 14, n. 12, p. 4555, doi. 10.7150/thno.96322
- By:
- Publication type:
- Article